AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Amwell's Q2 2025: Contradictions in Subscription Revenue and DHA Contract Renewal Impact Future Projections
Generated by AI AgentAinvest Earnings Call Digest
Tuesday, Aug 5, 2025 8:35 pm ET1min read
AMWL--
Aime Summary
Revenue Growth and Subscription Software Expansion:
- American Well CorporationAMWL-- reported total revenue of $70.9 million for Q2 2025, 13% higher than Q2 2024.
- Subscription software revenue was 57% of total revenue at $40.4 million, up 47% from a year ago.
- The growth was driven by strategic client deployments, including the Military Health Systems' digital-first initiative.
Operational Efficiency and Cost Initiatives:
- Adjusted EBITDA improved to a negative $4.7 million, compared to a negative $35 million in Q2 of last year.
- R&D expenses declined by 12.2% year-over-year to $18.3 million.
- These improvements were attributed to streamlining teams, harnessing AI, and reshaping operations.
Government Contract Renewals and Future Opportunities:
- The company received a one-year extension for its SaaS software platform powering the Military Health System's digital-first initiatives.
- The contract's annualized subscription revenue value increased slightly compared to previous billings.
- The renewal is expected to serve as a foundation for additional software revenue expansion beyond the current contract value.
Visit Metrics and Revenue Trends:
- Approximately 1.2 million visits were completed in Q2, which is 22.3% lower than the previous year.
- Average revenue per visit was $73, a 9% decrease year-over-year, but normalized visits were flat.
- These trends reflect a mix shift towards virtual primary care and specialty programs, which has positive implications for growth and adoption.
Aime SummaryRevenue Growth and Subscription Software Expansion:
- American Well CorporationAMWL-- reported total revenue of $70.9 million for Q2 2025, 13% higher than Q2 2024.
- Subscription software revenue was 57% of total revenue at $40.4 million, up 47% from a year ago.
- The growth was driven by strategic client deployments, including the Military Health Systems' digital-first initiative.
Operational Efficiency and Cost Initiatives:
- Adjusted EBITDA improved to a negative $4.7 million, compared to a negative $35 million in Q2 of last year.
- R&D expenses declined by 12.2% year-over-year to $18.3 million.
- These improvements were attributed to streamlining teams, harnessing AI, and reshaping operations.
Government Contract Renewals and Future Opportunities:
- The company received a one-year extension for its SaaS software platform powering the Military Health System's digital-first initiatives.
- The contract's annualized subscription revenue value increased slightly compared to previous billings.
- The renewal is expected to serve as a foundation for additional software revenue expansion beyond the current contract value.
Visit Metrics and Revenue Trends:
- Approximately 1.2 million visits were completed in Q2, which is 22.3% lower than the previous year.
- Average revenue per visit was $73, a 9% decrease year-over-year, but normalized visits were flat.
- These trends reflect a mix shift towards virtual primary care and specialty programs, which has positive implications for growth and adoption.
Discover what executives don't want to reveal in conference calls
Latest Articles
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc's editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet